All In Biotech

Drug Trial Radar · NCT06679881

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

170

Planned (sponsor's estimate)

Start

Feb 1, 2025

Primary completion

Aug 19, 2031

Study completion Aug 19, 2031

Sponsor

Lead sponsor
Pharvaris Netherlands B.V.Industry
Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • DeucrictibantDrug

    Deucrictibant extended-release tablet for once daily oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs), and TEAEs leading to study drug discontinuationTime frame: Up to Week 240
  2. Change in heart rateTime frame: Up to Week 240
  3. Change in blood pressureTime frame: Up to Week 240
  4. Change in body temperatureTime frame: Up to Week 240
  5. Number of participants with clinically significant changes in HematologyTime frame: Up to Week 240
  6. Number of participants with clinically significant changes in Clinical ChemistryTime frame: Up to Week 240
  7. Number of participants with clinically significant changes in UrinalysisTime frame: Up to Week 240
  8. Change from Baseline electrocardiograms (ECGs)Time frame: Up to Week 240

Locations

67 sites in 23 countries. Site status is shown where the registry gives one.

  • Study Site

    Birmingham, Alabama

  • Study Site

    Scottsdale, Arizona

  • Study Site

    Little Rock, Arkansas

  • Study Site

    San Diego, California

  • Study Site

    Santa Monica, California

  • Study Site

    Walnut Creek, California

  • Study Site

    Colorado Springs, Colorado

  • Study Site

    Wheaton, Illinois

  • Study Site

    St Louis, Missouri

  • Study Site

    Las Vegas, Nevada

  • Study Site

    Hershey, Pennsylvania

  • Study Site

    Dallas, Texas

  • Study Site

    Milwaukee, Wisconsin

  • Study Site

    Corrientes, Argentina

  • Study Site

    Pilar, Argentina

  • Study Site

    Salta, Argentina

  • Study Site

    Box Hill, Australia

  • Study Site

    Parkville, Australia

  • Study Site

    Perth, Australia

  • Study Site

    Sydney, Australia

  • Study Site

    Vienna, Austria

  • Study Site

    Ribeirão Preto, Brazil

  • Study Site

    Salvador, Brazil

  • Study Site

    Santo André, Brazil

  • Study Site

    São Paulo, Brazil

  • Study Site

    São Paulo, Brazil

  • Study Site

    Sofia, Bulgaria

  • Study Site

    Edmonton, Canada

  • Study Site

    Montreal, Canada

  • Study Site

    Beijing, China

  • Study Site

    Grenoble, France

  • Study Site

    Berlin, Germany

  • Study Site

    Frankfurt, Germany

  • Study Site

    Munich, Germany

  • Study Site

    Hong Kong, Hong Kong

  • Study Site

    Budapest, Hungary

  • Study Site

    Dublin, Ireland

  • Study Site

    Milan, Italy

  • Study Site

    Padova, Italy

  • Study Site

    Palermo, Italy

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.